Molecular Medicine Reports Molecular Medicine Reports 1791-2997 1791-3004 D.A. Spandidos 10.3892/mmr.2017.7880 mmr-17-01-0003 Review Biological functions and role of CCN1/Cyr61 in embryogenesis and tumorigenesis in the female reproductive system YangRui ChenYing ChenDaozhen Wuxi Maternity and Child Health Care Hospital Affiliated to Nanjing Medical University, Wuxi, Jiangsu 214002, P.R. China Correspondence to: Professor Ying Chen or Professor Daozhen Chen, Wuxi Maternity and Child Health Care Hospital Affiliated to Nanjing Medical University, 48 Huaishu Lane, Chong'an, Wuxi, Jiangsu 214002, P.R. China, E-mail: yingchen8@163.com, E-mail: chendaozhen@163.com 012018 26102017 17 1 3 10 13122016 18092017 Copyright: © Yang et al. 2018 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Cysteine-rich angiogenic inducer 61 (CCN1/Cyr61) is a prompt response transcription product activated by growth factors. As a member of the CCN family, it mediates cell survival, proliferation, differentiation, migration, adhesion and synthesis of the extracellular matrix by binding directly to the integrins and heparin sulfate proteoglycans or activating multiple signaling transduction pathways. It has previously been demonstrated that CCN1/Cyr61 exhibits an important role in the female reproductive system during embryogenesis and tumorigenesis. However, the functions of CCN1/Cyr61 in the female reproductive system have not been systematically investigated, therefore, the primary aim of the present review is to introduce the role and function of CCN1/Cyr61 in the female reproductive system. The current review presents the molecular structure and biological function of CCN1/Cyr61 and provides detailed data on its expression pattern and contribution to the female reproductive system, including the role in embryogenesis and tumorigenesis.

 cysteine rich angiogenic inducer 61 reproductive system embryogenesis tumorigenesis Introduction

Cysteine-rich angiogenic inducer 61 (CCN1/Cyr61) was originally revealed to act as a growth factor-inducible immediate-early gene, present in serum and platelet-derived growth factor-stimulated mouse BALB/c 3T3 cells (1). As a member of CCN family, it was first cloned by O'Brien in 1990 via differential hybridization screening of a cDNA library from BALB/c 3T3 clone A31 cells (2). The CCN family is composed of six members including CCN1/Cyr61, connective tissue growth factor, nephroblastoma overexpressed, Wnt-1-induced secreted protein (WISP)-1, WISP-2 and WISP-3 (3). CCN1/Cyr61 is a basic secreted protein localized on the cell surface, cell interior and the extracellular matrix (ECM). CCN1/Cyr61 targets cells including fibroblasts, epithelial cells, endothelial cells, smooth muscle cells and neurons through integrins and heparin sulfate proteoglycan (HSPG) receptors. CCN1/Cyr61 exhibits a variety of functions in differing target cells. The biological properties of CCN1/Cyr61 in the regulation of cell survival, proliferation, differentiation, migration, adhesion and synthesis of ECM have been demonstrated to be important in the progression of embryogenesis and tumorigenesis in the female reproductive system.

 CCN1/Cyr61 molecular structure

Complementary DNA encoding the human CCN1/Cyr61 protein was isolated by Jay et al (4) from human embryonic tissues in 1997. It is located on human chromosome 1p22.3 and contains 5 exons, interspaced with 4 introns. As presented in Fig. 1, the first exon encodes the mRNA that is translated into secretory signal peptide protein. The following 4 exons (E2-E5) encode a mosaic Cyr61 domain. The transcription of Cyr61 may be promptly induced by a wide range of environmental stimulatory factors, including vascular endothelial growth factor (VEGF), fibroblast growth factor, platelet-derived growth factor (PDGF), transforming growth factor (TGF)-β, sphingosine 1-phosphate, angiotensin II and lipopolysaccharides, in addition to physical and environmental inputs including shear stress, mechanical stretch and oxygen deprivation (5–7). The open reading frame of CCN1/Cyr61 encodes a protein of 381 amino acid including 38 conserved cysteines.

Sequence analysis revealed the presence of a mosaic structure to the CCN1/Cyr61 protein, including four highly conserved modules (3). As presented in Fig. 1, from the N- to the C-terminal, the four structurally distinct modules of CCN1/Cyr61 are insulin-like growth factor binding protein (IGFBP)-like domain, von Willebrand factor type C repeats (vWC) domain, thrombospondin type 1 (TSP-1) repeat homology domain, and the C-terminal domain that contains a cysteine-knot (8). Currently, the four structurally distinct modules of CCN1/Cyr61 have been important targets to explore the biological function of the protein. Module I is the binding domain of IGFBP which consists of 68 amino acids and shares homology with the cysteine-rich N-terminal region of traditional IGFBPs. A previous study suggested that CCN1/Cyr61 demonstrates a low affinity to IGFs (9). Module II consists of 68 amino acids and includes a vWC domain which exists in vWC factor, mucoprotein, thrombospondin and collagenous fiber. Module II may additionally have a role in oligomerization (3). Module III contains a motif firstly identified in TSP-1 repeat homology and subsequently observed in various extracellular proteins. TSP-1 homology is involved in binding to soluble and matrix sulfated glycoconjugates (10). A previous study revealed that Module III contains cell attachment sites (11). Module IV, the C-terminal domain, is present in PDGF, nerve growth factor and TGF-β. It has been hypothesized that Module IV may be involved with cell surface receptors (12). The modular structural organization of the CCN1/Cyr61 protein suggests that its diverse biological functions may result from the combined actions of individual modules, either acting independently or in conjugation. The interaction of the module and different factors endows CCN1/Cyr61 with complex biological effects in the organism tissues, cell environment and at all developmental stages.

 CCN1/Cyr61 biological functions

CCN1/Cyr61 coordinates the essential activities of life and demonstrates a diverse functional pattern in various pathological and physiological conditions, in addition to its role in various tissues and cells. CCN1/Cyr61 primarily binds to integrins and HSPGs in a cell-type specific manner, and thus mediates various biological activities via these interactions.

CCN1/Cyr61 mediates cellular processes

CCN1/Cyr61 has been reported to mediate numerous cellular activities, including cell adhesion, migration, proliferation and apoptosis. CCN1/Cyr61 is a cell adhesion protein, which is associated with the adhesion activities of endothelial cells, fibroblasts cells, smooth muscle cells, monocytes and platelets, through binding to particular integrins (Table I) (13–18). Integrin αvβ3, αvβ5, αIIbβ3, α6β1, and αMβ2 serve as adhesion receptors for CCN1/Cyr61 on different cell types which are summarized in Table I. It has previously been demonstrated that cell adhesive properties of CCN1/Cyr61 in human umbilical vein endothelial cells are mediated through interaction with integrin αvβ3 (14). In addition, it was demonstrated that CCN1/Cyr61 mediates endothelial cell adhesion through interaction with α6β1 (13). CCN1/Cyr61 promotes cell adhesion indirectly by altering the structure of the ECM protein. Kireeva et al (19) reported that CCN1/Cyr61 mediates cell and ECM and cell-cell adhesion by connecting with ECM and the cell membrane.

Cell migration is a complex biological process which involves a series of stimulating factors, signaling pathways and molecular mechanisms. It has been demonstrated that CCN1/Cyr61 regulates cell migration of fibroblasts and endothelial cells. Zhang et al (20) firstly verified that PDGF-induced CCN1/Cyr61 exhibits a key role in regulating smooth muscle cell migration by connecting intracellular PDGF-extracellular signal-regulated kinase and jun N-terminal kinase signals with integrin/focal adhesion kinase (FAK) signaling. Fibroblasts may suppress the inflammatory response, and may be considered as a novel target for the therapy of inflammation. Huang et al (21) demonstrated that CCN1/Cyr61 markedly facilitates rheumatoid arthritis (RA) fibroblast-like synoviocyte invasion and migration and may act as a promising therapeutic target for RA treatment. Wei et al (22) suggested that CCN1/Cyr61 expression is significantly associated with the metastasis of gastric cardia adenocarcinoma (GCA). It has therefore been hypothesized that CCN1/Cyr61 may act as a metastatic biomarker for evaluating the prognosis of GCA and a potential molecular target for anti-metastatic therapy of GCA.

In addition to promoting cell adhesion and migration, CCN1/Cyr61 regulates cell survival and apoptosis. The overexpression of CCN1/Cyr61 activates the nuclear factor (NF)-κB pathway and induces hepatic stellate cell apoptosis through endoplasmic reticulum stress and initiation of the unfolded protein response (23). Conversely, CCN1/Cyr61 expression promotes kidney tubular epithelial cell proliferation and cell apoptosis is inhibited (21). The functions of CCN1/Cyr61 in promoting cell survival or inducing apoptosis in different cell-types is important to elucidate its role in tissue reconstruction.

 CCN1/Cyr61 and angiogenesis

Previous studies have suggested CCN1/Cyr61 is a primary physiological mediator of angiogenesis. CCN1/Cyr61 modulates vascular formation in vitro directly through binding to αvβ3 to enhance the endothelial cell adhesion, migration, proliferation and microtubule formation, or indirectly by accommodating the activity of VEGF/VEGF receptor. You et al (24) suggested that CCN1/Cyr61 induces the expression of monocyte chemoattractant protein-1 to mediate angiogenesis via the ανβ3 integrin, FAK, phosphoinositide-3-kinase/Akt Serine/Threonine Kinase 1 (Akt) and the IKB kinase signaling pathways in monkey chorioretinal vessel endothelial cells RF/6A (24). A previous study investigating pancreatic neuroendocrine tumors revealed a positive correlation between CCN1/Cyr61 expression levels and tumor angiogenesis, which suggests an ancillary function of CCN1/Cyr61 in vascular development (25). CCN1/Cyr61 was revealed to be expressed in the placenta, cardiovascular, skeletal and nervous systems during embryonic development. CCN1/Cyr61 expression levels are additionally significantly decreased in pre-eclamptic placentas (26). This suggests that CCN1/Cyr61 is involved in placental angiogenesis and may be important in the pathogenesis of pre-eclampsia. CCN1/Cyr61-deficient mice lead to a placental vasculogenesis deficiency with incomplete vascular nets. A previous study reported ~30% of mice died from the chorioallantoic junction defect in the early stage of pregnancy and the others died in the middle of pregnancy due to placental vascular insufficiency and extensive loss in the vasculature integrity (27). Overall, these results demonstrate that CCN1/Cyr61 is critically involved in developmental angiogenesis.

 CCN1/Cyr61 and chondrogenesis

CCNl/Cyr61 is important in cartilage cell differentiation and chondrogenesis. The expression of CCNl/Cyr61 is closely associated with angiogenesis and the process of the differentiation from marrow stromal cells (MSC) to chondrocytes during embryogenesis (28). In adult cartilage, Chijiiwa et al (29) demonstrated that CCNl/Cyr61 is involved in chondrocyte cloning in osteoarthritic cartilage by inhibiting the activity of ADAM metallopeptidase with thrombospondin type 1 motif 4 (ADAMTS; aggrecanase-1). Conversely, the emergence of CCNl/Cyr61 may lead to the replacement of bone tissue by cartilage through inducing angiogenesis. A previous study revealed that CCNl/Cyr61 may be associated with the induction of a passage-dependent decrease in chondrogenic differentiation and a passage-dependent increase in osteogenic potential of tonsil-derived MSC (30).

 CCN1/Cyr61 and the female reproductive system <sec> <title>CCN1/Cyr61 and reproduction

Mammalian reproduction is a complex process involving ovulation, fertilization, embryo development and implantation and the failure of any process may result in sterility, malformations or adverse pregnancy outcomes. Previous studies demonstrated that CCNl/Cyr61 is expressed on the corpus luteum (CL) (31), conceptus and endometrium in early pregnancy (32), trophoblastic origin of the placenta (33), midterm fetal smooth muscle vessel walls of the arterial circulatory system (34), endothelial cells of vessels surrounding the cloaca, embryonic hippocampal neurons (35) and mesodermal and ectodermal mesenchymal cells (28). It contributes to the process of embryogenesis including the implantation (36), fetal neovascularization (34), fetal brain development (35), fetal cartilaginous development (28) and fetal-maternal cross-talk (32). The abnormal expression of CCNl/Cyr61 may result in pre-eclampsia, epispadias, embryonic death resulting from disability of allantoic fusion and the disturbance of vascular dysplasia (34,37).

CL, which is a glandular-like structure rich in blood vessels and exhibits a key role in mammalian reproduction. The development of the follicle into the CL involves neovascularization, and previous studies have demonstrated that CCNl/Cyr61 may mediate this process (Fig. 2). Zhang et al (31) suggested that CCNl/Cyr61 is expressed in the CL of cows and the expression is upregulated at days 4, 6, 10 and 16 of CL. It was therefore hypothesized that the upregulation may be associated with the angiogenesis of the CL. A further study conducted by Romereim et al (38) demonstrated that the CCNl/Cyr61 gene is highly expressed in small luteal cells isolated from cows. These findings support the hypothesis that CCNl/Cyr61 is important in the development of the CL. However, the expression pattern, regulation and function of CCNl/Cyr61 in human CLs still remains unclear and requires further investigation.

Implantation is an important process during the early development of embryos. CCNl/Cyr61 has previously been suggested to act as a mediator for embryo implantation. It has previously been detected to be upregulated in the invasive extravillous trophoblasts and unclosed endometrial luminal epithelium surrounding the embryo (39). Pre-eclampsia is one of the common complications of pregnancy, which originates in the placenta and results in complication of maternal and fetal health (40). The hypothesis of the etiology has been recognized as insufficient invasion of trophoblast cells into the decidua and the obstruction of maternal spiral artery remodeling (41). This leads to an inadequate blood flow in the placenta and may result in the inhibition of placental development and intrauterine growth restrictions (42). Recombinant CCNl/Cyr61 protein-stimulated trophoblast cells demonstrate a stronger invasion ability compared with cells without the stimulus (43). Chen et al (33) revealed that CCNl/Cyr61 mRNA expression levels in placentas of pre-eclampsia cases are decreased compared with than those in normal pregnancies. Furthermore, Kipkeew et al (36) indicated that CCNl/Cyr61 and CCN3 promote the migration capability of trophoblast cells by activating FAK and Akt kinase. This evidence verified the hypothesis of a negative correlation between the expression of CCNl/Cyr61 and pre-eclampsia. These findings may act as a research foundation for the early diagnosis and prediction of pre-eclampsia through screening for expression of CCNl/Cyr61. Zhang et al (44) suggested that that micro (mi)RNA 155 contributes to pre-eclampsia development by downregulating CCNl/Cyr61. MiRNAs are relatively stable and the identification of circulating miRNAs involved in promoting the development of pre-eclampsia by regulating the expression of CCNl/Cyr61 in the plasma of pregnant woman, may aid in the clinical prediction of pre-eclampsia.

CCNl/Cyr61 is additionally important in the maintenance of the pregnancy and the embryonic development. Klein et al (32) demonstrated that CCNl/Cyr61 is co-expressed on the conceptus and endometrium in the early stage of pregnancy and involved the maintenance of the early pregnancy. It contributes to the cross-talk of the conceptus and endometrium through affecting the proliferation and differentiation of endometrial and trophectoderm cells and stimulation of endometrial-angiogenesis. Furthermore, previous studies have demonstrated that CCNl/Cyr61 regulates neovascularization and matrix remodeling in the process of embryogenesis. CCNl/Cyr61 gene knock-out mice often suffer from vascular anomalies of placenta and embryonic fatalities (34). The expression of CCNl/Cyr61 may be detected in endothelial cells of vessels surrounding the cloaca and the umbilical cord on gestational days 10 and 11.5 in mice, which suggests it may be involved in the development of human epispadias (37). In addition, the expression of CCNl/Cyr61 in fetal hippocampal neurons has been demonstrated to be increased compared with mature hippocampal neurons, which suggests it may exhibit an important role during development of the embryonic brain (35). Overall, CCNl/Cyr61 is important role in the female reproductive system.

 CCN1/Cyr61 and female reproductive tumors

It was previously demonstrated that CCNl/Cyr61 acts as a tumor-suppressor or promoter in different types of tumors depending on the complex external environment (45–47). CCNl/Cyr61 is involved in the occurrence and development of tumors through its role in tumor angiogenesis, tumor cell proliferation and apoptosis and tumor metastasis (25,47–49). An overview of the expression and function of CCNl/Cyr61 in female reproductive tumors is presented in Table II (50–61). Further research and understanding of the function of CCNl/Cyr61 in different types of cancer may provide a promising basis for cancer prognosis and therapy.

Uterine leiomyoma (UL) is the most common benign tumor of the female reproductive system, which is hormone dependent and results from smooth muscle cell proliferation (62). Molecular genetic studies have provided compelling evidence that abnormally expressed genes have an important influence on UL occurrence (63,64). CCNl/Cyr61 expression in UL is downregulated when compared with matched normal uterine smooth muscle cells, suggesting it may exhibit a tumor-suppressor role (50). Di Tommaso et al (51) revealed that estrogen upregulates the expression of the CCNl/Cyr61 gene in myometrium tissue, however has no influence on the expression of the CCNl/Cyr61 gene in fibroid tissue, detected via gene expression analysis. The results indicated that the expression of CCNl/Cyr61 may not be regulated by the estrogen receptor in uterine fibroids. Fundamental research was conducted by Wallace et al (52) to determine if hypoxia induced CCNl/Cyr61 secretion through the Endothelin-A (ETA) receptor in UL. However, the results identified that blockade of the ETA receptor demonstrated no significant influence on the increase of CCNl/Cyr61 expression under normoxic or hypoxic conditions and the secretion of CCNl/Cyr61 may not be regulated by the ETA receptor in UL. The exact mechanism still remains unclear and further investigation is required in the future.

Endometriosis (EMT) is one of the most common diseases of obstetrics and gynecology, and commonly associates with infertility in women of child-bearing age (65–67). The specific pathogenesis of EMT remains to be fully elucidated. Although EMT is a frequently occurring benign disease, it is characterized by malignant behaviors including recurrence and metastasis (68,69). At present, various pharmacotherapies and other methods have been proposed to treat EMT (70,71). However, their usage has been limited due to strong and obvious adverse effects (65,72). It was previously demonstrated that the expression of the CCNl/Cyr61 gene is controlled by estrogen and is enhanced in endometria of women suffering from EMT and in endometriotic lesions, suggesting that CCNl/Cyr61 may act as a useful maker gene for EMT (53). A further study identified that estrogen promotes the expression of the CCNl/Cyr61 gene during the early stages of EMT-like establishment and the CCNl/Cyr61 gene contributes to regulation of cell proliferation and the generation of vasculature in the development of lesions, using the conditional knockout mice lacking uterine CCNl/Cyr61 (54). Furthermore, Gashaw et al (73) demonstrated that the expression level of CCNl/Cyr61 is upregulated by hypoxia-inducible factor 1-α, through use of the benign endometrial cell line. The study suggests that targeting CCNl/Cyr61 signaling during the early stages of lesion establishment may provide a novel treatment method for EMT.

Endometrial cancer (EC) is a common malignant gynecological tumor, however non-invasive diagnostic tools for early and accurate diagnosis are still limited (74). Hormonal dysregulation is believed to contribute to the etiology of EC (75). Previous studies demonstrated that long-term replacement estrogen therapy is associated with a type I EC and progestational hormone is not sufficient to prevent this (56). Estrogen may upregulate the expression of CCNl/Cyr61 and current data indicate that there is a significant increase of CCNl/Cyr61 expression in the endometrium of women with polycystic ovarian syndrome and premalignant lesions. Hence, measures to detect the expression of CCNl/Cyr61 may result in its use as an early diagnostic marker of type I EC cancer However, Chien et al (55) demonstrated that the expression level of Cyr61 is decreased in endometrial tumors compared with normal endometrium. At present, little is known regarding the antithetical function of CCNl/Cyr61 in EC. Previous findings from Witek et al (76) revealed that CCNl/Cyr61 genes expressed in all cancer grades and their expressions levels are potentially correlated with the survival of patients. Therefore, detecting the expression level of CCNl/Cyr61 may act as a novel non-invasive diagnostic tool for early and accurate diagnosis of EC.

Cervical cancer is one of the most common gynecological tumors occurring in women worldwide, with >190,000 newly diagnosed cases per year (77). The human papillomavirus infection is an important factor in the development of cervical cancer, and vaccination against it provides an effective way to prevent development of cervical cancer. However, the pathogenesis underlying cervical cancer remains unknown, and its incidence is increasing each year. Xie et al (58) demonstrated that CCNl/Cyr61 gene expression is downregulated in cervical cancer compared with normal tissues and its expression level is inversely correlated with miR-205 expression. miR-205 has been reported to contribute to the development of cervical cancer and regulate cell proliferation and migration in human cervical cancer cells. The identified inverse expression pattern between CCNl/Cyr61 and miR-205 suggests that CCNl/Cyr61 may be one of the target genes of miR-205. In addition, by performing genome-wide expression analysis of miRNAs, in addition to investigation of mRNAs in cervical cancer, Joy et al (57) demonstrated that CCNl/Cyr61 is a key gene involved in vascularization of tumors and suggests its expression level is negatively associated with the level of hsa-miR-221. The roles of CCNl/Cyr61 in human cervical cancer may provide novel insights into carcinogenesis and the clinical diagnosis.

Ovarian cancer is the leading cause of gynecological malignancy-associated mortalities worldwide and the symptoms are insidious in onset (78,79). The search for novel biomarkers for early diagnosis in ovarian carcinoma may provide effective medical support. Lee et al (60) demonstrated that CCNl/Cyr61 promotes ovarian cancer cell proliferation and inhibits apoptosis by regulating p53 and NF-κB expression through the phosphoinositide-3-kinase/AKT Serine/Threonine kinase/mechanistic target of rapamycin signaling pathways. Bartel et al (59) revealed that CCNl/Cyr61 is preferentially expressed in high grade serous carcinomas. It was demonstrated that CCNl/Cyr61 expression is significantly upregulated in ovarian epithelial carcinoma tissue compared with benign ovarian tumor tissue samples and the levels of CCNl/Cyr61 are associated with lymph node metastases (61). CCNl/Cyr61 may therefore be useful in targeted diagnosis and therapy in ovarian epithelial carcinoma.

 Conclusions

The present review systematically clarified the biological functions of CCN1/Cyr61 and its associated roles in the female reproductive system, including embryogenesis and tumorigenesis. CCNl/Cyr61 may regulate numerous cellular activities, angiogenesis and chondrogenesis. It is important in the reproduction and the occurrence and development of tumors in the reproductive system. However, the underlying mechanism that results in CCNl/Cyr61 acting as a tumor-suppressor or tumor-promoter in different types reproductive system tumors, remains to be fully elucidated, due to the complicated external environment, including complex crosstalk of intracellular molecules and multi-module activated signal transduction pathways.

 Acknowledgements

The present review was supported by the National Natural Science Foundation of China (grant nos. 81671473 and 81602728), the Youth Talent's Project of Jiangsu Province (grant no. QNRC2016164) and Provincial Foundation of Jiangsu Province (grant nos. BK20131151 and BE2016633).

 Abbreviations ECM

extracellular matrix

 HSPGs

heparin sulfate proteoglycans

 Cyr61/CCN1

cysteine-rich angiogenic inducer 61

 VEGF

vascular endothelial growth factor

 PDGF

platelet-derived growth factor

 TGF

transforming growth factor

 IGFBP

insulin-like growth factor binding protein

 vWC

von Willebrand factor type C repeats

 TSP-1

thrombospondin type 1

 FAK

integrin/focal adhesion kinase

 GCA

gastric cardia adenocarcinoma

 MSC

marrow stromal cells

 EMT

endometriosis

 EC

endometrial cancer

 References LauLFNathansDIdentification of a set of genes expressed during the G0/G1 transition of cultured mouse cellsEMBO J43145315119853841511554634 O'BrienTPYangGPSandersLLauLFExpression of cyr61, a growth factor-inducible immediate-early geneMol Cell Biol1035693577199010.1128/MCB.10.7.35692355916360792 BorkPThe modular architecture of a new family of growth regulators related to connective tissue growth factorFEBS Lett327125130199310.1016/0014-5793(93)80155-N7687569 JayPBergé-LefrancJLMarsollierCMéjeanCTaviauxSBertaPThe human growth factor-inducible immediate early gene, CYR61, maps to chromosome 1pOncogene1417531757199710.1038/sj.onc.12009869135077 Borkham-KamphorstESchaffrathCVan de LeurEHaasUTihaaLMeurerSKNevzorovaYALiedtkeCWeiskirchenRThe anti-fibrotic effects of CCN1/CYR61 in primary portal myofibroblasts are mediated through induction of reactive oxygen species resulting in cellular senescence, apoptosis and attenuated TGF-β signalingBiochim Biophys Acta1843902914201410.1016/j.bbamcr.2014.01.02324487063 ChenYDuXYFunctional properties and intracellular signaling of CCN1/Cyr61J Cell Biochem10013371345200710.1002/jcb.2119417171641 ChinLHHsuSPZhongWBLiangYCInvolvement of cysteine-rich protein 61 in the epidermal growth factor-induced migration of human anaplastic thyroid cancer cellsMol Carcinog55622632201610.1002/mc.2230825773758 RachfalAWBrigstockDRStructural and functional properties of CCN proteinsVitam Horm7069103200510.1016/S0083-6729(05)70003-015727802 BerschneiderBKönigshoffMWNT1 inducible signaling pathway protein 1 (WISP1): A novel mediator linking development and diseaseInt J Biochem Cell Biol43306309201110.1016/j.biocel.2010.11.01321109017 ChoiJLinAShrierELauLFGrantMBChaqourBDegradome products of the matricellular protein CCN1 as modulators of pathological angiogenesis in the retinaJ Biol Chem2882307523089201310.1074/jbc.M113.475418237986763743481 LinJHuoRWangLZhouZSunYShenBWangRLiNA novel anti-Cyr61 antibody inhibits breast cancer growth and metastasis in vivoCancer Immunol Immunother61677687201210.1007/s00262-011-1135-y22048717 QinZFisherGJQuanTCysteine-rich protein 61 (CCN1) domain-specific stimulation of matrix metalloproteinase-1 expression through aVb3 integrin in human skin fibroblastsJ Biol Chem2881238612394201310.1074/jbc.M112.424358235043243636922 HengECHuangYBlackSAJrTrackmanPCCCN2, connective tissue growth factor, stimulates collagen deposition by gingival fibroblasts via module 3 and alpha6- and beta1 integrinsJ Cell Biochem98409420200610.1002/jcb.20810164403221435777 KireevaMLLamSCLauLFAdhesion of human umbilical vein endothelial cells to the immediate-early gene product Cyr61 is mediated through integrin alphavbeta3J Biol Chem27330903096199810.1074/jbc.273.5.30909446626 ChenNChenCCLauLFAdhesion of human skin fibroblasts to Cyr61 is mediated through integrin alpha 6beta 1 and cell surface heparan sulfate proteoglycansJ Biol Chem2752495324961200010.1074/jbc.M00304020010821835 GrzeszkiewiczTMLindnerVChenNLamSCLauLFThe angiogenic factor cysteine-rich 61 (CYR61, CCN1) supports vascular smooth muscle cell adhesion and stimulates chemotaxis through integrin alpha(6)beta(1) and cell surface heparan sulfate proteoglycansEndocrinology14314411450200210.1210/endo.143.4.873111897702 SchoberJMChenNGrzeszkiewiczTMJovanovicIEmesonEEUgarovaTPYeRDLauLFLamSCIdentification of integrin alpha(M)beta(2) as an adhesion receptor on peripheral blood monocytes for Cyr61 (CCN1) and connective tissue growth factor (CCN2): Immediate-early gene products expressed in atherosclerotic lesionsBlood9944574465200210.1182/blood.V99.12.445712036876 JedsadayanmataAChenCCKireevaMLLauLFLamSCActivation-dependent adhesion of human platelets to Cyr61 and Fisp12/mouse connective tissue growth factor is mediated through integrin alpha(IIb)beta(3)J Biol Chem2742432124327199910.1074/jbc.274.34.2432110446209 KireevaMLMoFEYangGPLauLFCyr61, a product of a growth factor-inducible immediate-early gene, promotes cell proliferation, migration, and adhesionMol Cell Biol1613261334199610.1128/MCB.16.4.13268657105231116 ZhangFHaoFAnDZengLWangYXuXCuiMZThe matricellular protein Cyr61 is a key mediator of platelet-derived growth factor-induced cell migrationJ Biol Chem29082328242201510.1074/jbc.M114.623074256230724375479 HuangTLMuNGuJTShuZZhangKZhaoJKZhangCHaoQLiWNZhangWQDDR2-CYR61-MMP1 signaling pathway promotes bone erosion in rheumatoid arthritis through regulating migration and invasion of fibroblast-like synoviocytesJ Bone Miner Res32407418201710.1002/jbmr.299327653023 WeiJYuGShaoGSunAChenMYangWLinQCYR61 (CCN1) is a metastatic biomarker of gastric cardia adenocarcinomaOncotarget73106731078201610.18632/oncotarget.8845271055105058739 Borkham-KamphorstESteffenBTVan de LeurEHaasUTihaaLFriedmanSLWeiskirchenRCCN1/CYR61 overexpression in hepatic stellate cells induces ER stress-related apoptosisCell Signal283442201610.1016/j.cellsig.2015.10.01326515130 YouJJYangCHYangCMChenMSCyr61 induces the expression of monocyte chemoattractant protein-1 via the integrin avb3, FAK, PI3K/Akt, and NF-kB pathways in retinal vascular endothelial cellsCell Signal26133140201410.1016/j.cellsig.2013.08.02624063814 HuangYTLanQPonsonnetLBlanquetMChristoforiGZaricJRüeggCThe matricellular protein CYR61 interferes with normal pancreatic islets architecture and promotes pancreatic neuroendocrine tumor progressionOncotarget716631674201610.18632/oncotarget.641126625209 LiXLiCDongXGouWMicroRNA-155 inhibits migration of trophoblast cells and contributes to the pathogenesis of severe preeclampsia by regulating endothelial nitric oxide synthaseMol Med Rep10550554201410.3892/mmr.2014.221424806148 LauLFCCN1 and CCN2: Blood brothers in angiogenic actionJ Cell Commun Signal6121123201210.1007/s12079-012-0169-z228334633421018 O'BrienTPLauLFExpression of the growth factor-inducible immediate early gene cyr61 correlates with chondrogenesis during mouse embryonic developmentCell Growth Differ364565419921419914 ChijiiwaMMochizukiSKimuraTAbeHTanakaYFujiiYShimizuHEnomotoHToyamaYOkadaYCCN1 (Cyr61) is overexpressed in human osteoarthritic cartilage and inhibits ADAMTS-4 (Aggrecanase 1) activityArthritis Rheumatol6715571567201510.1002/art.3907825709087 YuYParkYSKimHSKimHYJinYMJungSCRyuKHJoICharacterization of long-term in vitro culture-related alterations of human tonsil-derived mesenchymal stem cells: Role for CCN1 in replicative senescence-associated increase in osteogenic differentiationJ Anat225510518201410.1111/joa.12229251558984292752 ZhangBTsangPCPateJLMosesMAA role for cysteine-rich 61 in the angiogenic switch during the estrous cycle in cows: Regulation by prostaglandin F2alphaBiol Reprod85261268201110.1095/biolreprod.110.086645214902423142255 KleinCNovel equine conceptus?endometrial interactions on Day 16 of pregnancy based on RNA sequencingReprod Fertil DevMay52015(Epub ahead of print)25940503 ChenXLiuYXuXChenHCorrelation of Cyr61 and CTGF in placentas from the late pre-eclamptic pregnancyJ Perinat Med40199200201210.1515/jpm-2011-003522905356 MoFEMunteanAGChenCCStolzDBWatkinsSCLauLFCYR61 (CCN1) is essential for placental development and vascular integrityMol Cell Biol2287098720200210.1128/MCB.22.24.8709-8720.200212446788139880 MalikARUrbanskaMGozdzASwiechLJNagalskiAPeryczMBlazejczykMJaworskiJCyr61, a matricellular protein, is needed for dendritic arborization of hippocampal neuronsJ Biol Chem28885448559201310.1074/jbc.M112.411629233622793605668 KipkeewFKirschMKleinDWuellingMWinterhagerEGellhausACCN1 (CYR61) and CCN3 (NOV) signaling drives human trophoblast cells into senescence and stimulates migration propertiesCell Adh Migr10163178201610.1080/19336918.2016.1139265267447714853050 DraakenMProskeJSchrammCWittlerLBartelsENöthenMMReutterHLudwigMEmbryonic expression of the cysteine rich protein 61 (CYR61) gene: A candidate for the development of human epispadiasBirth Defects Res A Clin Mol Teratol88546550201010.1002/bdra.2066820641097 RomereimSMSummersAFPohlmeierWEZhangPHouXTalbottHACushmanRAWoodJRDavisJSCuppASGene expression profiling of bovine ovarian follicular and luteal cells provides insight into cellular identities and functionsMol Cell Endocrinol439379394201710.1016/j.mce.2016.09.02927693538 ChenYNiHMaXHHuSJLuanLMRenGZhaoYCLiSJDiaoHLXuXGlobal analysis of differential luminal epithelial gene expression at mouse implantation sitesJ Mol Endocrinol37147161200610.1677/jme.1.0200916901931 WuPKwokCSHaththotuwaRKotroniasRABabuAFryerAAMyintPKChew-GrahamCAMamasMAPre-eclampsia is associated with a twofold increase in diabetes: A systematic review and meta-analysisDiabetologia5925182526201610.1007/s00125-016-4098-x27646865 HodginsSPre-eclampsia as underlying cause for perinatal deaths: Time for actionGlob Health Sci Pract3525527201510.9745/GHSP-D-15-00350266816994682577 ChaiworapongsaTChaemsaithongPYeoLRomeroRPre-eclampsia part 1: Current understanding of its pathophysiologyNat Rev Nephrol10466480201410.1038/nrneph.2014.10225003615 ZhangXYanGDiaoZSunHHuYNUR77 inhibits the expression of TIMP2 and increases the migration and invasion of HTR-8/SVneo cells induced by CYR61Placenta33561567201210.1016/j.placenta.2012.04.00522551568 ZhangYDiaoZSuLSunHLiRCuiHHuYMicroRNA-155 contributes to preeclampsia by down-regulating CYR61Am J Obstet Gynecol202466e1e7201020113684 HuangJGaoKLinJWangQMicroRNA-100 inhibits osteosarcoma cell proliferation by targeting Cyr61Tumour Biol3510951100201410.1007/s13277-013-1146-824317814 SarkissyanSSarkissyanMWuYCardenasJKoefflerHPVadgamaJVIGF-1 regulates Cyr61 induced breast cancer cell proliferation and invasionPLoS One9e103534201410.1371/journal.pone.0103534250620884111618 JohnsonSKStewartJPBamRQuPBarlogieBvan RheeFShaughnessyJDJrEpsteinJYaccobySCYR61/CCN1 overexpression in the myeloma microenvironment is associated with superior survival and reduced bone diseaseBlood12420512060201410.1182/blood-2014-02-555813250611784186535 ShigeokaMUrakawaNNishioMTakaseNUtsunomiyaSAkiyamaHKakejiYKomoriTKomaYYokozakiHCyr61 promotes CD204 expression and the migration of macrophages via MEK/ERK pathway in esophageal squamous cell carcinomaCancer Med4437446201510.1002/cam4.401256200884380969 MaityGMehtaSHaqueIDharKSarkarSBanerjeeSKBanerjeeSPancreatic tumor cell secreted CCN1/Cyr61 promotes endothelial cell migration and aberrant neovascularizationSci Rep44995201410.1038/srep04995248333094023131 ArslanAAGoldLIMittalKSuenTCBelitskaya-LevyITangMSTonioloPGene expression studies provide clues to the pathogenesis of uterine leiomyoma: New evidence and a systematic reviewHum Reprod20852863200510.1093/humrep/deh69815705628 Di TommasoSMassariSMalvasiABozzettiMPTinelliAGene expression analysis reveals an angiogenic profile in uterine leiomyoma pseudocapsuleMol Hum Reprod19380387201310.1093/molehr/gat00723355533 WallaceKChatmanKSpencerSKJohnsonVLaMarcaB‘Special research presentation’ endothelin regulation of cyr61 in uterine leiomyomasFertil Steril102Supple106201410.1016/j.fertnstert.2014.07.365 ZhaoYLiQKatzenellenbogenBSLauLFTaylorRNBagchiICBagchiMKEstrogen-induced CCN1 is critical for establishment of endometriosis-like lesions in miceMol Endocrinol2819341947201410.1210/me.2014-1080253214134250364 KleinRStillerSGashawIEpidermal growth factor upregulates endometrial CYR61 expression via activation of the JAK2/STAT3 pathwayReprod Fertil Dev24482489201210.1071/RD1033522401280 ChienWKumagaiTMillerCWDesmondJCFrankJMSaidJWKoefflerHPCyr61 suppresses growth of human endometrial cancer cellsJ Biol Chem2795308753096200410.1074/jbc.M41025420015471875 FournierADossusLMesrineSVilierABoutron-RuaultMCClavel-ChapelonFChabbert-BuffetNRisks of endometrial cancer associated with different hormone replacement therapies in the E3 N cohort, 1992–2008Am J Epidemiol180508517201410.1093/aje/kwu14625008104 JoyJEpigenetic regulation of key genes involved in cervical malignancy442014 XieHZhaoYCaramutaSLarssonCLuiWOmiR-205 expression promotes cell proliferation and migration of human cervical cancer cellsPLoS One7e46990201210.1371/journal.pone.0046990230565513463520 BartelFBalschunKGradhandEStraussHGDittmerJHauptmannSInverse expression of cystein-rich 61 (Cyr61/CCN1) and connective tissue growth factor (CTGF/CCN2) in borderline tumors and carcinomas of the ovaryInt J Gynecol Pathol31405415201210.1097/PGP.0b013e31824d189122833079 LeeKBByunHJParkSHParkCYLeeSHRhoSBCYR61 controls p53 and NF-kB expression through PI3K/Akt/mTOR pathways in carboplatin-induced ovarian cancer cellsCancer Lett3158695201210.1016/j.canlet.2011.10.01622078465 LinYXuTTianGCuiMCysteine-rich, angiogenic inducer, 61 expression in patients with ovarian epithelial carcinomaJ Int Med Res42300306201410.1177/030006051350526824595148 PoLKLiuGYDevelopment of uterine smooth muscle tumour of uncertain malignant potential (STUMP) after laparoscopic myomectomy of an atypical leiomyomaJ Minim Invasive Gynecol22S231201510.1016/j.jmig.2015.08.81327679126 JosephNMSolomonDAFrizzellNRabbanJTZaloudekCGargKMorphology and immunohistochemistry for 2SC and FH aid in detection of fumarate hydratase gene aberrations in uterine leiomyomas from young patientsAm J Surg Pathol3915291539201510.1097/PAS.000000000000052026457356 KubínováKMáraMHorákPKuzelDGenetic factors in etiology of uterine fibroidsCeska Gynekol7758602012In Czech22536642 HashimAbu HAromatase inhibitors for endometriosis-associated infertility; Do we have sufficient evidence?Int J Fertil Steril102702772016276956085023037 BhattiMArnoldAKetheeswaranANesbitt-HawesEDeansRAbbottJA comparison of examination and surgical findings in women with endometriosisJ Minim Invasive Gynecol22S55S56201510.1016/j.jmig.2015.08.14927679274 ModotteWPModottiCCDiasDSBueloni-DiasFNRodriguesNPEndometriosis and infertility setup during hysterossalpingogramJ Minim Invasive Gynecol22S178201510.1016/j.jmig.2015.08.65727678960 CozzolinoMNasioudisDSistiGCocciaMEMalignant transformation of vaginal endometriosis-a review of literatureGynecol Obstet Invest82105112201710.1159/00044919827618565 TobiumeTKotaniYTakayaHNakaiHTsujiISuzukiAMandaiMDeterminant factors of postoperative recurrence of endometriosis: Difference between endometrioma and painEur J Obstet Gynecol Reprod Biol2055459201610.1016/j.ejogrb.2016.07.51627566223 LinKZhanHMaJXuKWuRZhouCLinJSilencing of SRA1 regulates ER expression and attenuates the growth of stromal cells in ovarian endometriosisReprod Sci24836843201710.1177/193371911667003627694140 OharaFAbdala-RibeiroHSRodriguesFCAldrighiJMRibeiroPAOutcomes of laparoscopic treatment of rectosigmoid endometriosis: The linear nodulectomy and the segmental ressectionJ Minim Invasive Gynecol22S95201510.1016/j.jmig.2015.08.25427679386 SeyhanAAtaBUncuGThe impact of endometriosis and its treatment on ovarian reserveSemin Reprod Med33422428201510.1055/s-0035-156782026594869 GashawIStillerSBöingCKimmigRWinterhagerEPremenstrual regulation of the pro-angiogenic factor CYR61 in human endometriumEndocrinology14922612269200810.1210/en.2007-156818202125 YanokuraMBannoKIidaMIrieHUmeneKMasudaKKobayashiYTominagaEAokiDMicroRNAS in endometrial cancer: Recent advances and potential clinical applicationsEXCLI J141901982015265350324614112 DjatiWidodo MSRifa'iMRole of MicroRNAs in carcinogenesis that potential for biomarker of endometrial cancerAnn Med Surg (Lond)7913201610.1016/j.amsu.2016.01.091270067674786758 WitekŁJanikowskiTBodzekPOlejekAMazurekUExpression of tumor suppressor genes related to the cell cycle in endometrial cancer patientsAdv Med Sci61317324201610.1016/j.advms.2016.04.00127218895 ParkinDMBrayFFerlayJPisaniPEstimating the world cancer burden: Globocan 2000Int J Cancer94153156200110.1002/ijc.144011668491 LongRoche KAngaritaAMCristelloALippittMHaiderAHBowieJVFaderANTergasAI‘Little big things’: A qualitative study of ovarian cancer survivors and their experiences with the health care systemJ Oncol Pract12e974e980201610.1200/JOP.2015.00749227601509 YokoyamaYFutagamiMWatanabeJSatoNTeradaYMiuraFSugiyamaTTakanoTYaegashiNKojimaharaTRedistribution of resistance and sensitivity to platinum during the observation period following treatment of epithelial ovarian cancerMol Clin Oncol2212218201424649335

Gene and modular domain structure of CCN1/Cyr61. The CCN1/Cyr61 gene is transcribed into RNA and then translated into the protein. Each exon and its corresponding RNA and protein is depicted as a rectangle with a unique color. The module name of the protein is presented under the rectangle. The binding sites of integrin and HSPGs in the CCN1/Cyr61 protein are marked as dotted lines. CCN1/Cyr61, cysteine-rich angiogenic inducer 61; UTR, untranslated region; IGFBP, insulin-like growth factor binding protein; vWC, von Willebrand factor type C repeats; TSP-1, thrombospondin type 1; HSPG, heparan sulfate proteoglycans.

Expression and function of CCNl/Cyr61 in the CLs. The expression of CCNl/Cyr61 is upregulated in CL and promotes angiogenesis. CCN1/Cyr61, cysteine-rich angiogenic inducer 61; CL, corpus luteum.

Adhesion receptor for CCN1/Cyr61 on different cell types.

Author, year Cell types Integrins (Refs.)
Heng, 2006 Endothelial cells αvβ3, α6β1 (13,14)
Kireeva, 1998 Fibroblasts cell α6β1 (15)
Grzeszkiewicz, 2002 Smooth muscle cells α6β1 (16)
Schober, 2002 Monocytes αMβ2 (17)
Jedsadayanmata, 1999 Platelets αIIbβ3 (18)

Cyr61/CCN1, cysteine-rich angiogenic inducer 61.

Expression and function of CCNl/Cyr61 in female reproductive tumors.

Author, Year Female reproductive tumors Expression level Function (Refs.)
Arslan, 2005; Di Tommaso, 2013; Wallace, 2014 UL Downregulated Suppressor of UL (50–52)
Zhao, 2014; Klein, 2012 EMT Upregulated by estrogen or HIF-α Promoter of EMT cell proliferation, generation of vasculature (53–54)
Chien, 2004; Fournier, 2014 EC Downregulated in endometrial tumors; Up-regulated in PCOS Suppress growth of endometrial correlated with patient survival (55–56)
Joy, 2014; Xie, 2012 Cervical cancer Downregulated Target therapy, clinical diagnosis (57,58)
Bartel, 2012; Lee, 2012; Lin, 2014 Ovarian cancer Upregulated Promotes ovarian cancer cell proliferation and inhibits apoptosis, associated with lymph node metastases (59–61)

Cyr61/CCN1, cysteine-rich angiogenic inducer 61; UL, uterine leiomyoma; EMT, endometriosis; EC, endometrial cancer; PCOS, polycystic ovarian syndrome; HIF-α, hypoxia-inducible factor- α.